No Data
No Data
No Data
No Data
No Data
嘉和生物-B:2023年度報告
Futu NewsApr 25 17:06 · Announcements
As a result of the exercise of share options, Jiahe Bio-B (06998.HK) issued 4.442,400 shares
Jiahe Bio-B (06998.HK) announced that on April 10, 2024, the company issued 4.442,400 shares due to the exercise of share options by director Guo Feng under the pre-initial public offering share option scheme.
Zhitong FinanceApr 10 21:51
Intraday quick overview | The three major indices rose sharply, the Keji Index rose more than 2%, Bilibili rose nearly 8%, and JD and Meituan rose more than 5%
Biotech stocks rose, with Yao Ming Biotech up more than 6%, Genting Xinyao by more than 5%, Kingsray Biotech by more than 4%, and BeiGene Shenzhou by nearly 2%; Apple concept stocks generally rose, Ruisheng Technology and Gaowei Electronics by about 5%, and Shunyu Optics and Qiutai Technology by about 2%.
Futu NewsMar 28 10:44
Jiahe Bio-B (06998) announced 2023 results. Losses attributable to owners of about 674 million yuan narrowed 7.65% year-on-year
Jiahe Bio-B (06998) announced its 2023 results. The total revenue was zero, and the 2022 revenue was about 159...
Zhitong FinanceMar 27 23:33
GENOR-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023 AND PROPOSED ADOPTION OF THE EIGHTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION
Futu NewsMar 27 22:43 · Announcements
China's Drug Regulator Accepts Genor Biopharma's New Breast Cancer Drug Application; Shares Up 7%
Genor Biopharma Holdings (HKG:6998) said China's National Medical Products Administration officially accepted its new drug application for GB491 combined with Letrozole for advanced breast cancer trea
MT NewswiresMar 14 10:25
No Data
No Data